Here are three things to know:
1. CartiHeal’s proprietary implant is designed for joint surface lesion treatment.
2. The first two U.S. patients were enrolled in the Agili-C Investigational Device Exemption pivotal study.
3. In Europe and Israel, 80 patients have been enrolled and treated in the study, which aims to demonstrate Agili-C’s superiority over microfracture and debridement to treat cartilage or osteochondral defects in the knee.
More articles on devices:
Life Spine reports device revenue growth: 3 details
25%+ of hip arthroscopy patients still get opioids 3 months after surgery: 5 things to know
DePuy Synthes, Medtronic, NuVasive & more: 9 device company notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
